Claritas Pharmaceuticals, Inc.

CLAS.H

CA1806342061

Biotechnology & Medical Research

End-of-day quote Toronto S.E. Other stock markets 06:00:00 2022-07-18 pm EDT			5-day change	1st Jan Change
0.025 ^CAD	-16.67%		-.--%	-.--%

2021	Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	MT
2021	Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	CI

Claritas Pharmaceuticals, Inc.(TSXV:CLAS) added to S&P/TSX Venture Composite Index

April 19, 2021 at 12:00 am EDT

Latest news about Claritas Pharmaceuticals, Inc.

Claritas Pharmaceuticals : Updates Proposed Financing with Obsidian, Receives Australian Tax Credit, Starts Phase 1 Study of R-107	21-08-18	MT
Claritas Pharmaceuticals, Inc. Announces Data from Study Demonstrating Effectiveness of Nitric Oxide in Patients with Severe Covid-19 Pneumonia as Validation of the Company’s Nitric Oxide-Releasing Compound, R-107	21-07-26	CI
Claritas Pharmaceuticals : Reports Additional Data in Animal Model of Pulmonary Arterial Hypertension Treatment, R-107	21-07-21	MT
Claritas Pharmaceuticals, Inc. Announces Additional Data in Validated Animal Model of PAH Demonstrating Ability of R-107 to Prevent, Treat, and Reverse Established Disease	21-07-21	CI
Claritas Pharmaceuticals : 1-For-20 Share Consolidation Effective July 23	21-07-20	MT
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) dropped from S&P/TSX Venture Composite Index	21-07-19	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-28	CI
Claritas Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2020	21-04-30	CI
Claritas Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt	21-04-29	CI
Claritas Pharmaceuticals : In Agreement with CMAX Clinical Research for Phase 1 Clinical Study of Nitric Oxide-Releasing Drug, R-107	21-04-21	MT
Claritas Pharmaceuticals, Inc. Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107	21-04-21	CI
Claritas Pharmaceuticals, Inc.(TSXV:CLAS) added to S&P/TSX Venture Composite Index	21-04-19	CI
Claritas Pharmaceuticals : Announces Letter of Intent to Acquire Worldwide Rights to Develop R-107 Drug Compound	21-04-14	MT
Claritas Pharmaceuticals, Inc. entered into a binding Letter of Intent to acquire Exclusive Worldwide Rights of R-107 from Salzman Group Israel, Salzman Group Pty. Ltd. and Salzman Group, Inc. for $20.1 million.	21-04-13	CI
Kalytera Therapeutics, Inc. will Change its Name to Claritas Pharmaceuticals, Inc	21-04-12	CI
Kalytera Therapeutics, Inc. will Change its Ticker to CLAS from KLY	21-04-12	CI
Claritas to Expand R-107 Program to Include Treatment of Sepsis, the Leading Cause of Death in COVID-19 Patients	21-04-08	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling In Vitro Genotoxicity Studies with R-107	21-04-01	CI
Claritas Pharmaceuticals, Inc. Appoints Perenlei Enkhbaatar as an Independent Member of the Company’s Board of Directors, Effective Immediately	21-03-26	CI
Claritas Pharmaceuticals, Inc. Announces Board Changes	21-03-18	CI
Claritas Pharmaceuticals, Inc. Announces Completion of Canine Toxicology Studies	21-03-17	CI
Claritas Pharmaceuticals, Inc. Announces Completion of IND-Enabling Rodent Toxicology Studies with R-107	21-03-12	CI
Claritas (Formerly Kalytera Therapeutics, Inc.) Announces Addition of Professor Salvatore Cuzzocrea to the Board of Directors	21-03-05	CI
Claritas (Formerly Kalytera Therapeutics) Announces Additional Program to Reduce the Rate and Spread of Covid-19 with Prophylactic R-107 Nasal Spray Designed	21-03-04	CI
Claritas to Collaborate with Salzman Group and Other Companies to Accelerate Development of R-107 for Treatment of Vaccine-Resistant Covid-19, Influenza, and Other Viral Infections	21-03-03	CI

Chart Claritas Pharmaceuticals, Inc.

Duration

Period

More charts

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Companyâs products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

Sector

Biotechnology & Medical Research

More about the company

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CLARITAS PHARMACEUTICALS, INC.	-.--%	692K
IQVIA HOLDINGS INC.	+0.34%	42.86B
MODERNA, INC.	+11.55%	42.74B
LONZA GROUP AG	+44.30%	41.36B
CELLTRION, INC.	-6.20%	27.68B
ICON PUBLIC LIMITED COMPANY	+5.31%	25.15B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.63B
MEDPACE HOLDINGS, INC.	+27.48%	12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.20%	11.92B
UNITED THERAPEUTICS CORPORATION	+6.78%	11.21B

Other Biotechnology & Medical Research